Biotech investors had a great deal to be thankful for heading into the Thanksgiving holiday. With just one month to go before biotech closes the curtains on another year, the sector appears to be back on track and stands poised to finish 2015 in positive territory, a performance which is much better than some pundits were predicting when valuations nosedived during August and September as the heated debate over drug prices got into high gear.
Read More
Cloud-based high-performance computing is beginning to prove its worth in drug development research. The next logical step is its application in modernizing the clinical trial process by making trial enrollment and management much more efficient. Read More
Despite headline-grabbing controversies over the high cost of cancer, hepatitis C and other drugs in the U.S., the path to a projected $1.4 trillion in global total spending on medicines in 2020 will be driven not just by pricey prescriptions in developed markets, but also by increased access to medicines in low- and middle-income countries, according to a new report by the IMS Institute for Healthcare Informatics. Read More
